Apr 10, 2024, 09:52
David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC
David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn:
“Immunotherapy might become a novel standard of care in intermediate-stage HCC.
PETAL is the first study to focus on mechanisms of synergy between TACE and PD-1 inhibition at Imperial College London.”
Proceed to the article.
Source: David Pinato/LinkedIn
Aug 27, 2024, 03:21